Enzon Inc. (NASDAQ:ENZN) of South Plainfield, N.J., said it filed aU.S. patent application to register the trademark "ONCASPAR"for its PEG-L-asparaginase drug, which is under FDA review.ONCASPAR is used to treat patients with acute lymphoblasticleukemia who are hypersensitive or allergic to the unmodifiedform of L-asparaginase.

(c) 1997 American Health Consultants. All rights reserved.

No Comments